Fresenius Medical Care AG (ETR: FME)
Germany
· Delayed Price · Currency is EUR | Market Cap | 12.87B |
| Revenue (ttm) | 19.24B |
| Net Income (ttm) | 658.94M |
| Shares Out | 293.41M |
| EPS (ttm) | 2.25 |
| PE Ratio | 19.54 |
| Forward PE | 13.36 |
| Dividend | 1.19 (2.71%) |
| Ex-Dividend Date | n/a |
| Volume | 164,809 |
| Open | 43.75 |
| Previous Close | 43.90 |
| Day's Range | 43.20 - 43.85 |
| 52-Week Range | 32.51 - 46.20 |
| Beta | 0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 25, 2025 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized... [Read more]
Financial Performance
In 2023, Fresenius Medical Care AG's revenue was 19.45 billion, an increase of 0.29% compared to the previous year's 19.40 billion. Earnings were 499.00 million, a decrease of -25.90%.
Financial StatementsNews
Fresenius Medical Care Awarded Mechanical Circulatory Support Agreement with Premier, Inc. for the Novalung® ECMO System
Strategic Relationship: Agreement expands access to ECMO solutions for hospitals, health systems and patients in the U.S. nationwide. Wide Reach: 4,350+ Premier member hospitals and health systems in ...
Fresenius Medical Care AG (FMS) Stock Price Up 4.03% on Nov 16
Fresenius Medical Care AG (FMS) Stock Price Up 4.03% on Nov 16
‘If they don’t get care, they die’: the woman who runs the world’s largest kidney dialysis company
Helen Giza of FME is excited about the possibilities new drugs such as Ozempic could offer for renal patients New popular weight-loss drugs such as Wegovy and Ozempic come with an additional benefit: ...
Hard work paying off despite challenges from U.S. weather-related events: Fresenius Medical Care CEO
Helen Giza, the CEO of Fresenius Medical Care, discusses the German healthcare firm's third-quarter earnings.
Fresenius Medical Care AG (FMS) Q3 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ETCompany ParticipantsDominik Heger - Head, Investor...
Fresenius Medical Care AG 2024 Q3 - Results - Earnings Call Presentation
Hard work paying off despite challenges from U.S. weather-related events: Fresenius Medical Care CEO
Helen Giza, the CEO of Fresenius Medical Care, discusses the German healthcare firm's third-quarter earnings.
Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024
Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional E...
Fresenius Medical Care reports Q3 results
Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024
A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments. Company-wid...
Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips +
Discover 12 undercovered stocks from October 4th - 10th, including insights on WW International, Fresenius Medical Care, and Taseko Mines.
Fresenius Medical Care: Let's Look At The Upside
Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E. Click here to find out why I rate FMS stock a buy.
FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives
Fresenius Medical Care (NYSE: FMS) is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Through its network of mor...
Fresenius Medical Care Grows Number of U.S. Patients Using Company's Home Hemodialysis Machines, Launches NxStage® Versi®HD with GuideMe Software
Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapy This growth has generated greater adop...
Fresenius Medical Care CEO says strategy is working as company delivers on transformation efforts
Fresenius Medical Care CEO Helen Giza comments on the firm's second-quarter earning results.
Fresenius Medical Care AG (FMS) Q2 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS) Q2 2024 Earnings Call July 30, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin...
Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024
Organic revenue growth of +2.3% supported by both segments Care Delivery and Care Enablement Operating income1 and operating income margin1 increase driven by Care Enablement Additional FME25 savings ...
US FTC probing DaVita, Fresenius Medical, Politico reports
The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita and Fresenius Medical Care over allegations that the companies have been illegally thwarting smaller competitors, P...
Fresenius Medical Care: Significant Upside Remains
Fresenius Medical Care has underperformed since 2017, declining over 50% in the market. Despite the decline, the company remains a market leader in dialysis services with a strong product line. The co...
Fresenius Medical Care takes next important step towards goal to reduce CO2 emissions in its operations
Fresenius Medical Care enters virtual power purchase agreements for renewable energy to clearly step forward in reducing CO2 emissions footprint Company enacts five virtual power purchase agreements f...
Moody's and S&P change Fresenius Medical Care's rating outlook to stable
The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating FME is expected to maintain its good growth mome...
Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024
Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence Company-wide experts highlight robust anonymized dialysis database CONVINCE study and the remarkable...
Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets
Today's Annual General Meeting was the first one following the change in legal form completed in November 2023 Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an incre...
Fresenius Medical sees up to 2% US dialysis growth by year-end
The number of kidney dialysis sessions provided by Fresenius Medical Care in its top market, the United States, could rise by as much as 2% by the end of the year, its CEO said, as the impact of the p...
Fresenius Medical Care AG (FMS) Q1 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Dominik Heger - Head, IR Helen Giza - CEO and Chair Martin Fischer - CFO Conference C...